Cathie Wood's ARK ETFs have been active in the market on Thursday, 24 October 2024, with a series of notable transactions that reflect the investment firm's strategic positioning. The daily trade report reveals a mix of buys and sells across various sectors, with the largest dollar-value trade involving the sell-off of Tesla Inc (NASDAQ:TSLA) shares.
ARK ETFs sold a total of 85,456 shares of Tesla, resulting in a significant dollar value of $18,257,673. This move comes amidst a dynamic market environment for the electric vehicle giant, which has seen its shares experience volatility in recent months. The decision to reduce exposure to Tesla might be a tactical one, considering the company's performance and broader market trends.
Another major transaction involved Teradyne Inc (NASDAQ:TER), a provider of automated test equipment. ARK ETFs bought a substantial number of shares, totaling 132,546, with a dollar value of $16,492,698. This investment indicates ARK's confidence in Teradyne's growth prospects and its role in the technology sector.
In the biotech sphere, ARK ETFs continued to increase their stake in Crispr Therapeutics AG (NASDAQ:CRSP), purchasing 95,330 shares with a dollar value of $4,385,180. This follows a pattern of consistent buying in the gene-editing company, suggesting ARK's bullish outlook on the potential of CRISPR technology in healthcare.
Intellia Therapeutics Inc (NASDAQ:NTLA), another company specializing in genome editing, also saw significant investment from ARK ETFs. A total of 216,205 shares were bought, amounting to $4,311,127. This, too, reflects ARK's focus on innovative healthcare solutions and its belief in the long-term value of such disruptive technologies.
On the sell side, ARK ETFs divested from L3Harris Technologies Inc (NYSE:NYSE:LHX), a defense contractor, by selling 3,872 shares valued at $951,815. Additionally, ARK ETFs reduced their holdings in Markforged Holding Corp (NYSE:MKFG), a 3D printing company, by selling 315,011 shares with a dollar value of $1,439,600.
Cerus Corp (NASDAQ:CERS), a biomedical products company, continued to attract ARK's interest, with the firm buying 308,066 shares across different ETFs, totaling $495,986. This follows a trend of ARK accumulating shares in Cerus, indicating a positive outlook on the company's prospects.
Other trades included the sale of shares in Materialise NV (NASDAQ:MTLS) and Vertex Pharmaceuticals Inc (NASDAQ:VRTX), with ARK ETFs selling 146,179 and 5,008 shares valued at $744,051 and $2,354,010, respectively.
The daily trade report from Cathie Wood's ARK ETFs provides insights into the investment firm's market moves and strategic bets. With significant buys in companies at the forefront of technological and biomedical innovation and selective sells in other sectors, ARK's activities reflect its commitment to investing in disruptive growth opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.